| Date Filed | Type | Description |
| 10/10/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 09/28/2023 |
8-K
| Quarterly results |
| 08/21/2023 |
8-K
| Other Events Interactive Data |
| 08/15/2023 |
8-K
| Other Events Interactive Data |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 08/08/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/08/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/08/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/08/2023 |
4
| MANNING MARTHA E (SVP, GEN. COUNSEL & CORP. SEC.) has filed a Form 4 on MARINUS PHARMACEUTICALS, INC.|
Txns:
| Sold 2,169 shares
@ $9.54, valued at
$20.7k
Sold 11 shares
@ $8.93, valued at
$98.2 |
|
| 08/08/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/01/2023 |
8-K
| Quarterly results |
| 07/06/2023 |
SC 13G
| ADAGE CAPITAL PARTNERS GP, L.L.C. reports a 5.4% stake in Marinus Pharmaceuticals, Inc. |
| 05/17/2023 |
4
| Noonberg Sarah B. (Director) has filed a Form 4 on MARINUS PHARMACEUTICALS, INC.|
Txns:
| Granted 7,200 shares
@ $0
Granted 32,400 options to buy
@ $8.51, valued at
$275.7k
|
|
| 05/17/2023 |
3
| Noonberg Sarah B. (Director) has filed a Form 3 on MARINUS PHARMACEUTICALS, INC. |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 04/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/19/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 04/18/2023 |
8-K
| Quarterly results |
| 03/31/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 03/31/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 03/22/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/10/2023 |
8-K
| Other Events Interactive Data |
| 03/09/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/07/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| 683 Capital Management, LLC reports a 0.2% stake in Marinus Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G
| EVENTIDE ASSET MANAGEMENT, LLC reports a 6.6% stake in Marinus Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/08/2023 |
4
| Fischer Seth H. Z. (Director) has filed a Form 4 on MARINUS PHARMACEUTICALS, INC.|
Txns:
| Sold 1,018 shares
@ $6.54, valued at
$6.7k
|
|
| 02/08/2023 |
4
| Ezickson Elan (Director) has filed a Form 4 on MARINUS PHARMACEUTICALS, INC.|
Txns:
| Sold 750 shares
@ $6.56, valued at
$4.9k
|
|
| 02/08/2023 |
4
| Austin Charles (Director) has filed a Form 4 on MARINUS PHARMACEUTICALS, INC.|
Txns:
| Sold 1,073 shares
@ $6.49, valued at
$7k
|
|
| 01/30/2023 |
4
| Braunstein Scott (CHAIRMAN AND CEO) has filed a Form 4 on MARINUS PHARMACEUTICALS, INC.|
Txns:
| Granted 80,000 shares
@ $0
Granted 360,000 options to buy
@ $5.94, valued at
$2.1M
|
|
|